Loading clinical trials...
Loading clinical trials...
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine: A Range of Doses Will be Evaluated
Conditions
Interventions
Elismetrep (K-304) Dose Level 1
Elismetrep (K-304) Dose level 2
+3 more
Locations
66
United States
Central Research Associates, LLC (CRA) dba Flourish Research
Birmingham, Alabama, United States
AMR Mobile
Mobile, Alabama, United States
Wake Research/ Tucson Neuroscience Research
Tucson, Arizona, United States
Hope Clinical Research
Canoga Park, California, United States
WR-PRI, LLC (Encino)
Encino, California, United States
Marvel Clinical Research
Huntington Beach, California, United States
Start Date
March 5, 2025
Primary Completion Date
August 11, 2025
Completion Date
August 11, 2025
Last Updated
September 3, 2025
NCT01004263
NCT04089761
NCT01267864
NCT02745392
NCT03145467
NCT02185703
Lead Sponsor
Kallyope Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions